Colgate-Palmolive Company (CL) 10-Year Financial Performance & Capital Metrics

CL • • Industrial / General

Consumer DefensiveHousehold ProductsPersonal Care & CosmeticsSkincare & Hair Care

AboutColgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.Show more

Revenue $20.1B +3.3%
EBITDA $4.99B +6.2%
Net Income $2.89B +25.6%
EPS (Diluted) 3.51 +26.7%
Gross Margin 60.23% +4.2%
EBITDA Margin 24.81% +2.8%
Operating Margin 21.8% +2.7%
Net Margin 14.37% +21.6%
ROE 384.94% +47.5%
ROIC 38.64% +14.5%
Debt/Equity 15.65 +65.2%
Interest Coverage 15.01 +4.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 282.3%
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 17.6% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 2.6%
✓Healthy 5Y average net margin of 13.0%

✗Weaknesses

✗High debt to equity ratio of 15.6x
✗Expensive at 125.4x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.53%

5Y5.08%

3Y4.89%

TTM-0.05%

Profit (Net Income) CAGR

10Y2.86%

5Y4.07%

3Y10.08%

TTM1.32%

EPS CAGR

10Y4.05%

5Y5%

3Y11.24%

TTM2.29%

ROCE

10Y Avg39.12%

5Y Avg35.23%

3Y Avg35.62%

Latest39.96%

Peer Comparison

Skincare & Hair Care

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AXILAXIL Brands, Inc.	52.99M	7.79	77.90	-4.51%	3.26%	8.85%	2.9%	0.08
ULUnilever PLC	141.09B	64.70	28.25	1.94%	10.16%	61.19%	5.51%	1.36
CLColgate-Palmolive Company	66.87B	82.96	23.64	3.31%	14.47%	234.81%	5.3%	15.65
PGThe Procter & Gamble Company	337.05B	144.24	22.16	0.29%	19.74%	31.31%	4.17%	0.68
SLSNSolesence, Inc. Common Stock	107.22M	1.52	21.71	40.35%	1.72%	6.21%		1.02
EPCEdgewell Personal Care Company	861.43M	18.44	9.36	0.09%	2.94%	4.13%	20.26%	0.87
UGUnited-Guardian, Inc.	28.76M	6.26	8.82	11.91%	19.48%	18.52%	10.55%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	16.03B	15.2B	15.45B	15.54B	15.69B	16.47B	17.42B	17.97B	19.46B	20.1B
Revenue Growth %	-0.07%	-0.05%	0.02%	0.01%	0.01%	0.05%	0.06%	0.03%	0.08%	0.03%
Cost of Goods Sold+	6.66B	6.06B	6.13B	6.34B	6.42B	6.54B	7.13B	7.82B	8.21B	8B
COGS % of Revenue	0.42%	0.4%	0.4%	0.41%	0.41%	0.4%	0.41%	0.44%	0.42%	0.4%
Gross Profit+	9.37B	9.13B	9.32B	9.21B	9.28B	9.93B	10.29B	10.15B	11.25B	12.11B
Gross Margin %	0.58%	0.6%	0.6%	0.59%	0.59%	0.6%	0.59%	0.56%	0.58%	0.6%
Gross Profit Growth %	-0.07%	-0.03%	0.02%	-0.01%	0.01%	0.07%	0.04%	-0.01%	0.11%	0.08%
Operating Expenses+	5.4B	5.17B	5.31B	5.36B	5.51B	6.02B	6.41B	6.57B	7.12B	7.72B
OpEx % of Revenue	0.34%	0.34%	0.34%	0.34%	0.35%	0.37%	0.37%	0.37%	0.37%	0.38%
Selling, General & Admin	5.13B	4.88B	5.03B	5.08B	5.23B	5.73B	6.1B	6.25B	6.78B	7.81B
SG&A % of Revenue	0.32%	0.32%	0.33%	0.33%	0.33%	0.35%	0.35%	0.35%	0.35%	0.39%
Research & Development	274M	289M	285M	277M	281M	290M	307M	320M	343M	355M
R&D % of Revenue	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	-442M
Operating Income+	3.97B	3.96B	4.01B	3.85B	3.76B	3.91B	3.89B	3.58B	4.13B	4.38B
Operating Margin %	0.25%	0.26%	0.26%	0.25%	0.24%	0.24%	0.22%	0.2%	0.21%	0.22%
Operating Income Growth %	-0.05%	-0%	0.01%	-0.04%	-0.02%	0.04%	-0.01%	-0.08%	0.15%	0.06%
EBITDA+	4.42B	4.4B	4.48B	4.36B	4.28B	4.45B	4.44B	4.13B	4.7B	4.99B
EBITDA Margin %	0.28%	0.29%	0.29%	0.28%	0.27%	0.27%	0.25%	0.23%	0.24%	0.25%
EBITDA Growth %	-0.04%	-0%	0.02%	-0.03%	-0.02%	0.04%	-0%	-0.07%	0.14%	0.06%
D&A (Non-Cash Add-back)	449M	443M	475M	511M	519M	539M	556M	545M	567M	605M
EBIT	2.9B	3.89B	3.64B	3.66B	3.49B	3.81B	3.2B	2.83B	3.68B	4.25B
Net Interest Income+	-26M	-99M	-102M	-143M	-145M	-141M	-100M	-153M	-232M	-225M
Interest Income	107M	50M	51M	50M	47M	19M	17M	14M	55M	67M
Interest Expense	133M	149M	153M	193M	192M	160M	117M	167M	287M	292M
Other Income/Expense	-1.21B	-222M	-522M	-386M	-461M	-264M	-799M	-925M	-739M	-427M
Pretax Income+	2.76B	3.74B	3.49B	3.46B	3.3B	3.65B	3.09B	2.66B	3.39B	3.96B
Pretax Margin %	0.17%	0.25%	0.23%	0.22%	0.21%	0.22%	0.18%	0.15%	0.17%	0.2%
Income Tax+	1.22B	1.15B	1.31B	906M	774M	787M	749M	693M	937M	907M
Effective Tax Rate %	0.5%	0.65%	0.58%	0.69%	0.72%	0.74%	0.7%	0.67%	0.68%	0.73%
Net Income+	1.38B	2.44B	2.02B	2.4B	2.37B	2.69B	2.17B	1.78B	2.3B	2.89B
Net Margin %	0.09%	0.16%	0.13%	0.15%	0.15%	0.16%	0.12%	0.1%	0.12%	0.14%
Net Income Growth %	-0.37%	0.76%	-0.17%	0.19%	-0.01%	0.14%	-0.2%	-0.18%	0.29%	0.26%
Net Income (Continuing)	2.63B	2.59B	2.17B	2.56B	2.53B	2.86B	2.34B	1.97B	2.46B	3.05B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	255M	260M	303M	299M	441M	358M	362M	405M	348M	332M
EPS (Diluted)+	1.52	2.72	2.28	2.75	2.75	3.14	2.55	2.13	2.77	3.51
EPS Growth %	-0.36%	0.79%	-0.16%	0.21%	0%	0.14%	-0.19%	-0.16%	0.3%	0.27%
EPS (Basic)	1.53	2.74	2.30	2.76	2.76	3.15	2.56	2.13	2.78	3.53
Diluted Shares Outstanding	909.7M	898.4M	887.8M	873M	861.1M	859.3M	848.3M	838.8M	829.2M	822.5M
Basic Shares Outstanding	902.2M	891.8M	881.8M	870.6M	859.1M	856.8M	845M	836.4M	827.4M	817.7M
Dividend Payout Ratio	1.08%	0.62%	0.76%	0.66%	0.68%	0.56%	0.78%	0.95%	0.76%	0.62%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.38B	4.34B	4.64B	3.79B	4.18B	4.34B	4.4B	5.11B	5.28B	5.32B
Cash & Short-Term Investments	970M	1.31B	1.53B	726M	883M	888M	832M	775M	966M	1.26B
Cash Only	970M	1.31B	1.53B	726M	883M	888M	832M	775M	966M	1.1B
Short-Term Investments	0	0	0	0	0	0	0	0	0	160M
Accounts Receivable	1.43B	1.41B	1.48B	1.4B	1.44B	1.26B	1.3B	1.5B	1.59B	1.52B
Days Sales Outstanding	32.48	33.89	34.96	32.87	33.49	28.01	27.17	30.55	29.75	27.62
Inventory	1.18B	1.17B	1.22B	1.25B	1.4B	1.67B	1.69B	2.07B	1.93B	1.99B
Days Inventory Outstanding	64.63	70.5	72.69	71.99	79.64	93.4	86.64	96.84	86.02	90.71
Other Current Assets	807M	441M	403M	417M	456M	513M	576M	760M	793M	553M
Total Non-Current Assets+	7.57B	7.79B	8.04B	8.37B	10.86B	11.58B	10.64B	10.62B	11.11B	10.73B
Property, Plant & Equipment	3.8B	3.84B	4.07B	3.88B	3.75B	3.72B	3.73B	4.31B	4.58B	4.42B
Fixed Asset Turnover	4.22x	3.96x	3.80x	4.01x	4.18x	4.43x	4.67x	4.17x	4.25x	4.55x
Goodwill	2.1B	2.11B	2.22B	2.53B	3.51B	3.82B	3.28B	3.35B	3.41B	3.27B
Intangible Assets	1.35B	1.31B	1.34B	1.64B	2.67B	2.89B	2.46B	1.92B	1.89B	1.76B
Long-Term Investments	0	0	0	0	0	0	0	0	0	81M
Other Non-Current Assets	239M	224M	218M	168M	753M	857M	974M	904M	1.02B	1B
Total Assets+	11.96B	12.12B	12.68B	12.16B	15.03B	15.92B	15.04B	15.73B	16.39B	16.05B
Asset Turnover	1.34x	1.25x	1.22x	1.28x	1.04x	1.03x	1.16x	1.14x	1.19x	1.25x
Asset Growth %	-0.11%	0.01%	0.05%	-0.04%	0.24%	0.06%	-0.06%	0.05%	0.04%	-0.02%
Total Current Liabilities+	3.53B	3.31B	3.41B	3.34B	4.04B	4.4B	4.05B	4B	4.74B	5.76B
Accounts Payable	1.11B	1.12B	1.21B	1.22B	1.24B	1.39B	1.48B	1.55B	1.7B	1.8B
Days Payables Outstanding	60.8	67.67	72.15	70.37	70.37	77.77	75.73	72.42	75.53	82.4
Short-Term Debt	302M	13M	11M	12M	514M	267M	51M	25M	330M	660M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	79M	84M	101M	93M	70M	182M	93M	97M	122M	116M
Current Ratio	1.24x	1.31x	1.36x	1.14x	1.03x	0.99x	1.09x	1.28x	1.11x	0.92x
Quick Ratio	0.91x	0.96x	1.00x	0.76x	0.69x	0.61x	0.67x	0.76x	0.71x	0.58x
Cash Conversion Cycle	36.32	36.72	35.49	34.49	42.77	43.64	38.08	54.97	40.25	35.93
Total Non-Current Liabilities+	8.45B	8.8B	9.03B	8.62B	10.44B	10.41B	10.02B	10.92B	10.7B	9.74B
Long-Term Debt	6.25B	6.52B	6.57B	6.35B	7.33B	7.33B	7.19B	8.74B	8.22B	7.29B
Capital Lease Obligations	0	0	0	0	491M	476M	451M	397M	420M	456M
Deferred Tax Liabilities	233M	246M	204M	235M	507M	426M	395M	383M	361M	343M
Other Non-Current Liabilities	1.97B	2.04B	2.25B	2.03B	2.11B	2.18B	1.98B	1.4B	1.7B	1.66B
Total Liabilities	12B	12.11B	12.43B	11.96B	14.48B	14.82B	14.07B	14.93B	15.44B	15.5B
Total Debt+	6.55B	6.53B	6.58B	6.37B	8.48B	8.21B	7.83B	9.27B	9.06B	8.51B
Net Debt	5.58B	5.22B	5.04B	5.64B	7.6B	7.33B	7B	8.5B	8.1B	7.42B
Debt / Equity	-	384.29x	27.07x	32.31x	15.20x	7.46x	8.07x	11.50x	9.47x	15.65x
Debt / EBITDA	1.48x	1.48x	1.47x	1.46x	1.98x	1.85x	1.76x	2.24x	1.93x	1.71x
Net Debt / EBITDA	1.26x	1.19x	1.12x	1.29x	1.78x	1.65x	1.58x	2.06x	1.72x	1.49x
Interest Coverage	29.85x	26.58x	26.20x	19.95x	19.59x	24.44x	33.21x	21.47x	14.39x	15.01x
Total Equity+	-44M	17M	243M	197M	558M	1.1B	971M	806M	957M	544M
Equity Growth %	-1.03%	1.39%	13.29%	-0.19%	1.83%	0.97%	-0.12%	-0.17%	0.19%	-0.43%
Book Value per Share	-0.05	0.02	0.27	0.23	0.65	1.28	1.14	0.96	1.15	0.66
Total Shareholders' Equity	-299M	-243M	-60M	-102M	117M	743M	609M	401M	609M	212M
Common Stock	1.47B	1.47B	1.47B	1.47B	1.47B	1.47B	1.47B	1.47B	1.47B	1.47B
Retained Earnings	18.86B	19.92B	20.53B	21.61B	22.5B	23.7B	24.35B	24.57B	25.29B	26.14B
Treasury Stock	-18.1B	-19.14B	-20.18B	-21.2B	-22.06B	-23.05B	-24.09B	-25.13B	-26.02B	-27.36B
Accumulated OCI	-3.95B	-4.18B	-3.85B	-4.19B	-4.27B	-4.34B	-4.39B	-4.05B	-3.94B	-4.22B
Minority Interest	255M	260M	303M	299M	441M	358M	362M	405M	348M	332M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	2.95B	3.14B	3.05B	3.06B	3.13B	3.72B	3.33B	2.56B	3.75B	4.11B
Operating CF Margin %	0.18%	0.21%	0.2%	0.2%	0.2%	0.23%	0.19%	0.14%	0.19%	0.2%
Operating CF Growth %	-0.11%	0.07%	-0.03%	0%	0.03%	0.19%	-0.11%	-0.23%	0.47%	0.1%
Net Income	1.55B	2.59B	2.17B	2.56B	2.53B	2.86B	2.34B	1.97B	2.46B	3.05B
Depreciation & Amortization	449M	443M	475M	511M	519M	539M	556M	545M	567M	605M
Stock-Based Compensation	125M	123M	127M	109M	100M	107M	135M	125M	122M	135M
Deferred Taxes	-51M	56M	383M	107M	17M	-120M	-132M	-78M	-98M	-77M
Other Non-Cash Items	1B	-159M	10M	-74M	-95M	-48M	625M	723M	244M	51M
Working Capital Changes	-122M	92M	-115M	-155M	65M	381M	-197M	-726M	455M	344M
Change in Receivables	-75M	-17M	-15M	-79M	19M	138M	-84M	-227M	-37M	-56M
Change in Inventory	-13M	-4M	-8M	-58M	-77M	-251M	-72M	-333M	194M	-100M
Change in Payables	0	0	0	0	0	0	0	0	0	516M
Cash from Investing+	-685M	-499M	-471M	-1.17B	-2.1B	-878M	-592M	-1.6B	-742M	-534M
Capital Expenditures	-691M	-593M	-553M	-436M	-335M	-410M	-567M	-696M	-705M	-561M
CapEx % of Revenue	0.04%	0.04%	0.04%	0.03%	0.02%	0.02%	0.03%	0.04%	0.04%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-59M	57M	38M	7M	0	3M	-25M	52M	-33M	37M
Cash from Financing+	-2.28B	-2.23B	-2.45B	-2.68B	-870M	-2.82B	-2.77B	-952M	-2.79B	-3.39B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-1.49B	-1.51B	-1.53B	-1.59B	-1.61B	-1.5B	-1.68B	-1.69B	-1.75B	-1.79B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	347M	446M	507M	329M	513M	-152M	400M	400M	398M	547M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	2.26B	2.55B	2.5B	2.62B	2.8B	3.31B	2.76B	1.86B	3.04B	3.55B
FCF Margin %	0.14%	0.17%	0.16%	0.17%	0.18%	0.2%	0.16%	0.1%	0.16%	0.18%
FCF Growth %	-0.11%	0.13%	-0.02%	0.05%	0.07%	0.18%	-0.17%	-0.33%	0.63%	0.17%
FCF per Share	2.48	2.84	2.82	3.00	3.25	3.85	3.25	2.22	3.67	4.31
FCF Conversion (FCF/Net Income)	2.13x	1.29x	1.51x	1.27x	1.32x	1.38x	1.54x	1.43x	1.63x	1.42x
Interest Paid	131M	162M	150M	194M	185M	188M	194M	151M	280M	302M
Taxes Paid	1.26B	932M	1.04B	847M	803M	845M	890M	945M	937M	933M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	206.41%	14358.82%	1556.92%	1090.91%	627.02%	324.89%	209.07%	200.9%	260.92%	384.94%
Return on Invested Capital (ROIC)	49.72%	55.16%	57.16%	51.92%	40.32%	35.37%	35.54%	31.13%	33.76%	38.64%
Gross Margin	58.44%	60.1%	60.33%	59.23%	59.12%	60.31%	59.08%	56.49%	57.82%	60.23%
Net Margin	8.63%	16.06%	13.1%	15.44%	15.08%	16.36%	12.43%	9.93%	11.82%	14.37%
Debt / Equity	-	384.29x	27.07x	32.31x	15.20x	7.46x	8.07x	11.50x	9.47x	15.65x
Interest Coverage	29.85x	26.58x	26.20x	19.95x	19.59x	24.44x	33.21x	21.47x	14.39x	15.01x
FCF Conversion	2.13x	1.29x	1.51x	1.27x	1.32x	1.38x	1.54x	1.43x	1.63x	1.42x
Revenue Growth	-7.19%	-5.23%	1.7%	0.58%	0.96%	4.96%	5.77%	3.13%	8.29%	3.31%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Oral, Personal and Home Care	13.82B	12.93B	13.16B	13.16B	13.17B	13.59B	14.11B	14.25B	15.17B	15.62B
Oral, Personal and Home Care Growth	-	-6.45%	1.79%	-0.05%	0.09%	3.19%	3.84%	1.02%	6.41%	2.97%
Pet Nutrition	2.21B	2.26B	2.29B	2.39B	2.52B	2.88B	3.31B	3.71B	4.29B	4.48B
Pet Nutrition Growth	-	2.35%	1.24%	4.19%	5.74%	14.18%	14.85%	12.14%	15.54%	4.50%

Frequently Asked Questions

Valuation & Price

Colgate-Palmolive Company (CL) has a price-to-earnings (P/E) ratio of 23.6x. This is roughly in line with market averages.

Growth & Financials

Colgate-Palmolive Company (CL) reported $20.10B in revenue for fiscal year 2024. This represents a 20% increase from $16.73B in 2011.

Colgate-Palmolive Company (CL) grew revenue by 3.3% over the past year. Growth has been modest.

Yes, Colgate-Palmolive Company (CL) is profitable, generating $2.91B in net income for fiscal year 2024 (14.4% net margin).

Dividend & Returns

Yes, Colgate-Palmolive Company (CL) pays a dividend with a yield of 2.62%. This makes it attractive for income-focused investors.

Colgate-Palmolive Company (CL) has a return on equity (ROE) of 384.9%. This is excellent, indicating efficient use of shareholder capital.

Colgate-Palmolive Company (CL) generated $3.44B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...